• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Guidance Maps Out Trial Design for COVID-19 Drugs

FDA Guidance Maps Out Trial Design for COVID-19 Drugs

May 18, 2020

Sponsors of drugs to treat or prevent COVID-19 should focus on populations that are the hardest-hit and least-represented in clinical trials, including minorities and the elderly, according to a new FDA guidance released last week.

The guidance encourages sponsors to locate trials in areas with higher concentrations of racial and ethnic minorities and even to consider conducting trials on geriatric patients located in nursing homes or elder care facilities.

The FDA “strongly recommends” trial designs that compare the investigational drug to placebo and standard of care, and notes that trial revisions may be necessary to keep up with important new discoveries that may alter the accepted standard of care.

The guidance also encourages trial designs that use an independent data monitoring committee to ensure subject safety and data integrity.

Sponsors also should be prepared to open new sites or close existing sites based on regional spread of the virus. And they should develop criteria in advance for stopping a trial in the case of drug futility or the risk of patient harm.

In a separate guidance issued last week, the FDA recommends sponsors begin COVID-19 drug development activities by requesting a pre-IND meeting with the agency. To move quickly, the FDA is consolidating the standard pre-IND meeting request and package development processes into a single step and establishing a multispecialty, multidisciplinary team to focus on proposal review.

Sponsors who already have an active IND or who have submitted a pre-IND request to expand an approved drug for a COVID-19 indication should submit a new meeting request for the COVID-19 indication.

The guidance outlines what information should be included in a pre-IND request for a COVID-19 trial and offers instructions for submitting requests to the agency.

To read the guidances, click here: https://bit.ly/2LrGgn6 and https://bit.ly/3dNiWwd.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing